Chambers Michael Andrew 4
4 · Sarepta Therapeutics, Inc. · Filed Aug 11, 2023
Insider Transaction Report
Form 4
Chambers Michael Andrew
Director
Transactions
- Purchase
Common Stock
2023-08-10$106.26/sh+31,570$3,354,628→ 213,331 total(indirect: By Trust) - Purchase
Common Stock
2023-08-10$105.90/sh+1,091$115,537→ 181,761 total(indirect: By Trust) - Purchase
Common Stock
2023-08-10$104.67/sh+2,206$230,902→ 180,670 total(indirect: By Trust)
Holdings
- 6,431
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $103.99 to $104.98, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105 to $106, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.01 to $106.83, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.